Posted by Michael Wonder on 12 Jun 2025
Gilead’s Trodelvy wins Korean coverage for breast cancer -- too late for some and still off-limits up front
12 June 2025 - It took two years, 100,000 signatures, and a wave of public pressure from patients and doctors. Now, Gilead Sciences’ Trodelvy (sacituzumab govitecan) is finally reimbursed in Korea for metastatic triple-negative breast cancer. But for many, the decision came too late to matter.
Effective 1 June 2025, coverage applies to third-line treatment of locally advanced or metastatic triple-negative breast cancer, as well as second-line use if recurrence occurs within a year of prior chemotherapy. Reimbursement also extends to third-line treatment of hormone receptor positive, HER2 negative breast cancer.
